Rectal cancer with paraneoplastic nephropathy: Association of vascular endothelial growth factor

Digestive Surgery

Volumn 21, Issue 5-6, 2004, Pages 455-457

  Taniguchi, Ken ^a,b,c   Fujioka, Hikaru ^a,b   Torashima, Yasuhiro ^b   Yamaguchi, Junzo ^b   Izawa, Kunihide ^b   Kanematsu, Takashi ^c  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b National Saga Hospital   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

Minimal change nephrotic syndrome; Paraneoplastic nephropathy; Rectal cancer; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADULT; ARTICLE; CANCER SURGERY; CASE REPORT; FEMALE; HUMAN; HYPOPROTEINEMIA; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE PERIOD; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY TUMOR; NEPHROTIC SYNDROME; PROTEIN EXPRESSION; PROTEINURIA; RECTUM CANCER; REMISSION; SURGICAL TECHNIQUE;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEPHROSIS, LIPOID; PARANEOPLASTIC SYNDROMES; RECTAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 16244412282     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083474     Document Type: Article

References (10)

1. Gandini E, Allaria P, Castiglioni A, d'Amato I, Schiaffino E, Giangrande A: Minimal change nephrotic syndrome with cecum adenocarcinoma. Clin Nephrol 1996;45:268-270.
2. 4+ lymphocytes. Nephron 1990;56:341-342.
3. 1 in children with idiopathic nephrotic syndrome. J Nephrol 2001;14:263-269.
4. Saxena S, Mittal A, Andal A: Pattern of interleukins in minimal-change nephrotic syndrome of childhood. Nephron 1993;65:56-61.
5. Cho BS, Lee CE, Pyun KH: Studies on the role of interleukin-4 and Fc eRII in the pathogenesis of minimal change nephrotic syndrome. J Korean Med Sci 1992;7:343-348.
6. Cascinu S, Graziano F, Catalano V, Barni S, Giordani P, Baldelli AM, Staccioli MP, Rossi C, Brenna A, Valenti A, Muretto P, Catalano G: Vascular endothelial growth factor and p53 expressions in liver and abdominal metastases from colon cancer. Tumour Biol 2003;24:77-81.
7. Akbulut H, Altuntas F, Akbulut KG, Ozturk G, Cindoruk M, Unal E, Icli F: Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine 2002;20:184-190.
8. Ueda Y, Yamagishi T, Samata K, Ikeya H, Hirayama N, Takashima H, Nakaike S, Tanaka M, Saiki I: A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155. Mol Cancer Ther 2003;2:1105-1111.
9. Giugliano G, Pasquali D, Notaro A, Brongo S, Nicoletti G, D'Andrea F, Bellastella A, Sinisi AA: Verapamil inhibits interleukin-6 and vascular endothelial growth factor production in primary cultures of keloid fibroblasts. Br J Plast Surg 2003;56:804-809.
10. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX. Shellito PC, Lauwers GY, Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.